Brought to you by 
Aviva, Axon in biochip development program
02 Sep 2021
Executive Summary
Biochip company Aviva Biosciences will make a $3.5mm equity investment in Axon Instruments (drug discovery technologies that combine biochips and cell biology) in exchange for an exclusive license to intellectual property and patch clamp biochips.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com